These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 30413151)

  • 21. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
    Jakate A; Blumenfeld AM; Boinpally R; Butler M; Borbridge L; Contreras-De Lama J; McGeeney D; Periclou A; Lipton RB
    Headache; 2021 Apr; 61(4):642-652. PubMed ID: 33818780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials.
    Stauffer VL; Wang S; Voulgaropoulos M; Skljarevski V; Kovacik A; Aurora SK
    Headache; 2019 Jun; 59(6):834-847. PubMed ID: 30942898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination.
    Raffaelli B; Mussetto V; Israel H; Neeb L; Reuter U
    J Headache Pain; 2019 Jun; 20(1):66. PubMed ID: 31159727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study.
    Ford JH; Stauffer VL; McAllister P; Akkala S; Sexson M; Ayer DW; Wang S
    Qual Life Res; 2021 Feb; 30(2):455-464. PubMed ID: 32944843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A long-term open-label safety study of galcanezumab in Japanese patients with migraine.
    Hirata K; Takeshima T; Sakai F; Tatsuoka Y; Suzuki N; Igarashi H; Nakamura T; Ozeki A; Yamazaki H; Skljarevski V
    Expert Opin Drug Saf; 2021 Jun; 20(6):721-733. PubMed ID: 33393835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine.
    Martinez JM; Hindiyeh N; Anglin G; Kalidas K; Hodsdon ME; Kielbasa W; Moser BA; Pearlman EM; Garces S
    Cephalalgia; 2020 Aug; 40(9):978-989. PubMed ID: 32340471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN).
    Ford J; Tassorelli C; Leroux E; Wang S; Ayer D; Nichols R; Detke H
    Qual Life Res; 2021 Jan; 30(1):105-115. PubMed ID: 32930994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reductions in acute medication use and healthcare resource utilization in patients with chronic migraine: a secondary analysis of a phase 3, randomized, double-blind, placebo-controlled study of galcanezumab with open-label extension (REGAIN).
    Tobin JA; Joshi S; Ford JH; Nichols RM; Foster SA; Ruff D; Detke HC; Aurora SK
    J Med Econ; 2022; 25(1):1030-1038. PubMed ID: 35971655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure.
    Ruff DD; Ford JH; Tockhorn-Heidenreich A; Sexson M; Govindan S; Pearlman EM; Wang SJ; Khan A; Aurora SK
    Cephalalgia; 2019 Jul; 39(8):931-944. PubMed ID: 31104507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials.
    Jedynak J; Eross E; Gendolla A; Rettiganti M; Stauffer VL
    J Headache Pain; 2021 May; 22(1):48. PubMed ID: 34049484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study.
    Goadsby PJ; Silberstein SD; Yeung PP; Cohen JM; Ning X; Yang R; Dodick DW
    Neurology; 2020 Nov; 95(18):e2487-e2499. PubMed ID: 32913018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
    Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
    Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies.
    Förderreuther S; Zhang Q; Stauffer VL; Aurora SK; Láinez MJA
    J Headache Pain; 2018 Dec; 19(1):121. PubMed ID: 30594122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures.
    Schwedt TJ; Kuruppu DK; Dong Y; Standley K; Yunes-Medina L; Pearlman E
    J Headache Pain; 2021 Mar; 22(1):15. PubMed ID: 33765912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine.
    Saccà F; Braca S; Sansone M; Miele A; Stornaiuolo A; De Simone R; Russo CV
    Headache; 2023 Jun; 63(6):788-794. PubMed ID: 37254581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study).
    Vernieri F; Altamura C; Brunelli N; Costa CM; Aurilia C; Egeo G; Fofi L; Favoni V; Pierangeli G; Lovati C; Aguggia M; d'Onofrio F; Doretti A; Di Fiore P; Finocchi C; Rao R; Bono F; Ranieri A; Albanese M; Cevoli S; Barbanti P;
    J Headache Pain; 2021 May; 22(1):35. PubMed ID: 33941080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Safety and Tolerability of Fremanezumab for Migraine Preventive Treatment in Japanese Outpatients: A Multicenter, Randomized, Open-Label Study.
    Sakai F; Suzuki N; Ning X; Ishida M; Usuki C; Iba K; Isogai Y; Koga N
    Drug Saf; 2021 Dec; 44(12):1355-1364. PubMed ID: 34687446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment.
    Dodick DW; Goadsby PJ; Lucas C; Jensen R; Bardos JN; Martinez JM; Zhou C; Aurora SK; Yang JY; Conley RR; Oakes T
    Cephalalgia; 2020 Aug; 40(9):935-948. PubMed ID: 32050782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double-blind studies.
    Ailani J; Pearlman E; Zhang Q; Nagy AJ; Schuh K; Aurora SK
    Eur J Neurol; 2020 Mar; 27(3):542-549. PubMed ID: 31595600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial.
    Schwedt TJ; Myers Oakes TM; Martinez JM; Vargas BB; Pandey H; Pearlman EM; Richardson DR; Varnado OJ; Cobas Meyer M; Goadsby PJ
    Neurol Ther; 2024 Feb; 13(1):85-105. PubMed ID: 37948006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.